[Bone Metastasis in Prostate Cancer]

Overview

Journal Urologe A

Specialty Urology

Date 2012 Jan 20

PMID 22258372

Citations 1

Authors

F Moltzahn

G N Thalmann

Affiliations

Soon will be listed here.

Abstract

Bone metastasis and skeletal complications have a devastating impact on the quality of life and are a major cause of morbidity in prostate cancer patients. In addition to established bone-targeted therapies, new drugs such as endothelin A receptor antagonists, MET and VEGFR-2 antagonists or radiopharmaceuticals are in the focus of development. The standard care in prostate cancer patients with bone metastases to prevent skeletal-related events (SRE) are bisphosphonates. Denosumab, a human monoclonal antibody against RANKL, appeared to be superior to zoledronic acid for prevention of SRE and has been shown to prolong bone metastases-free survival. In contrast to zoledronic acid, denosumab clearance is not dependent on kidney function and can be administered subcutaneously. Similar rates of toxicity were observed for both substances; however, long-term data for denosumab are limited.

Citing Articles

Antiprostate Cancer Activity of Ineupatolide Isolated from L.

Huang Y, Mao J, Zhang L, Guo H, Yan C, Chen M Biomed Res Int. 2021; 2021:5515961.

PMID: 33996996 PMC: 8105106. DOI: 10.1155/2021/5515961.

References

Vogt U, Bielawski K, Bosse U, Schlotter C . Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep. 2004; 12(5):1109-14. View

Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L . Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-22. PMC: 3090685. DOI: 10.1016/S0140-6736(10)62344-6. View

Saylor P, Smith M . Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009; 181(5):1998-2006. PMC: 2900631. DOI: 10.1016/j.juro.2009.01.047. View

Dearnaley D, Mason M, Parmar M, Sanders K, Sydes M . Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009; 10(9):872-6. PMC: 2748902. DOI: 10.1016/S1470-2045(09)70201-3. View

Carducci M, Padley R, Breul J, Vogelzang N, Zonnenberg B, Daliani D . Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003; 21(4):679-89. DOI: 10.1200/JCO.2003.04.176. View

Denoyelle C, Hong L, Vannier J, Soria J, Soria C . New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer. 2003; 88(10):1631-40. PMC: 2377117. DOI: 10.1038/sj.bjc.6600925. View

Lipton A, Steger G, Figueroa J, Alvarado C, Solal-Celigny P, Body J . Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007; 25(28):4431-7. DOI: 10.1200/JCO.2007.11.8604. View

Roelofs A, Thompson K, Ebetino F, Rogers M, Coxon F . Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des. 2010; 16(27):2950-60. DOI: 10.2174/138161210793563635. View

Koeneman K, Yeung F, Chung L . Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999; 39(4):246-61. DOI: 10.1002/(sici)1097-0045(19990601)39:4<246::aid-pros5>3.0.co;2-u. View

10.

Thiery J . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-54. DOI: 10.1038/nrc822. View

11.

Sun Y, Wang J, Shelburne C, Lopatin D, Chinnaiyan A, Rubin M . Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003; 89(3):462-73. DOI: 10.1002/jcb.10522. View

12.

Rack B, Juckstock J, Genss E, Schoberth A, Schindlbeck C, Strobl B . Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 2010; 30(5):1807-13. View

13.

Roelofs A, Thompson K, Gordon S, Rogers M . Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006; 12(20 Pt 2):6222s-6230s. DOI: 10.1158/1078-0432.CCR-06-0843. View

14.

Conte P, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D . Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996; 14(9):2552-9. DOI: 10.1200/JCO.1996.14.9.2552. View

15.

James N, Sydes M, Clarke N, Mason M, Dearnaley D, Anderson J . Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int. 2008; 103(4):464-9. DOI: 10.1111/j.1464-410X.2008.08034.x. View

16.

Melisi D, Caputo R, Damiano V, Bianco R, Veneziani B, Bianco A . Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer. 2005; 12(4):1051-8. DOI: 10.1677/erc.1.01061. View

17.

Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A . Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005; 25(3):144-51. DOI: 10.1089/jir.2005.25.144. View

18.

Jakob F, Seefried L, Ebert R . [Pathophysiology of bone metabolism]. Internist (Berl). 2008; 49(10):1159-60, 1162, 1164 passim. DOI: 10.1007/s00108-008-2113-0. View

19.

Stopeck A, Lipton A, Body J, Steger G, Tonkin K, De Boer R . Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28(35):5132-9. DOI: 10.1200/JCO.2010.29.7101. View

20.

van der Pluijm G, Que I, Sijmons B, Buijs J, Lowik C, Wetterwald A . Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res. 2005; 65(17):7682-90. DOI: 10.1158/0008-5472.CAN-04-4188. View